By Isabella Ciccone, MPH NeurologyLive
Published July 13, 2026
Key Takeaways
- Prespecified MCI analysis showed progressive p‑tau217 decline from ~26 weeks on 265 mg BID dosing, contrasting placebo increases and supporting target engagement in APOE4/4 carriers.
- Between-group biomarker differences correlated at week 78 with ADAS‑Cog13, CDR‑SB, and hippocampal volume, aligning biochemical effects with cognitive, functional, and vMRI signals.
- Overall trial missed the ADAS‑Cog primary endpoint in the full early-AD cohort, while mild-dementia participants demonstrated smaller, non–statistically significant p‑tau217 reductions versus placebo.
- APOE4/4 homozygotes (~15% of AD) accrue amyloid rapidly and have elevated ARIA risk on antiamyloid mAbs, making an oral oligomerization inhibitor without ARIA-E signal clinically attractive.
In a prespecified analysis presented at AAIC 2026, findings showed that plasma p-tau217 declined from baseline in valiltramiprosate-treated MCI patients compared with placebo over 78 weeks.
Newly presented biomarker findings from the phase 3 APOLLOE4 trial (NCT04770220) suggest that valiltramiprosate (Alzheon), an investigational oral small-molecule inhibitor of amyloid oligomer formation, may engage its intended target in patients with mild cognitive impairment (MCI) because of Alzheimer disease (AD) who carry 2 copies of the APOE4 allele.1
In the prespecified analysis, presented at the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15, in London, United Kingdom, participants with MCI treated with the agent showed a net 53% reduction in plasma phosphorylated tau 217 (p-tau217) relative to placebo over 78 weeks. Presented by lead author John Hey, PhD, chief scientific officer at Alzheon, these biomarker changes correlated with previously reported cognitive, functional, and imaging benefits.
